The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas / Baldini, L., Balzarotti, M., Bernardi, M., Bobbio, F., Brandes, A.a., Cappio, F., Corazzelli, G., Dell'Oro, S., Ferrari, A.j., Foppoli, M., Ilariucci, F., Montanari, M., Picozzi, P., Ponzoni, M., Reni, M., Spina, M., Stelitano, C., Tosoni, A., Zaja, F.. - In: NEUROLOGY. - ISSN 0028-3878. - 66:9(2006), pp. 1435-1438. [10.1212/01.wnl.0000210464.94122.e1]
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
ZAJA, Francesco
2006-01-01
Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
